/**
 * Structured Traffic Light Medication Checker content.
 * Generated by scripts/migrate-traffic-light-to-structured.ts
 */
import type { TrafficLightDocument } from './traffic-light-types';

export const TRAFFIC_LIGHT_DOCUMENT: TrafficLightDocument = {
  updated: 'February 2026',
  sections: [
  { id: 'green-zone', zone: 'green', title: 'üü¢ GREEN ZONE: Generally Suitable for 12 Months', blocks: [
    { type: 'paragraph', content: '**If patient stable, these medications can be prescribed for 12 months**' },
    { type: 'table', headers: ['Medication', 'Annual Monitoring Required', 'Notes'], rows: [['**Statins** (atorvastatin, simvastatin, rosuvastatin)', 'Lipids annually', 'LFTs NOT routinely required (BPAC)'], ['**Calcium channel blockers** (amlodipine, felodipine)', 'BP annually', '-'], ['**Beta blockers** (metoprolol, bisoprolol, atenolol)', 'BP, HR annually', 'Watch for symptomatic bradycardia'], ['**ICS** (fluticasone, budesonide)', 'Spirometry if available, technique check', '-'], ['**LABA/ICS combos** (Seretide, Symbicort)', 'Spirometry if available, technique check', '-'], ['**LAMA** (tiotropium)', 'Spirometry if available', 'No SA renewal needed (Dec 2025 change)'], ['**Oral contraceptives**', 'BP annually', 'Can dispense 6-month intervals'], ['**PPIs** (omeprazole, esomeprazole)', 'Usually none', 'Review need annually'], ['**Aspirin** (antiplatelet dose)', 'Annual bleeding risk assessment', '-'], ['**Clopidogrel, Ticagrelor**', 'Annual bleeding risk assessment', 'Usually post-ACS, specialist-initiated'], ['**SSRIs/SNRIs** (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, venlafaxine)', '**Annual review + discussion about duration**', '-'], ['**Mirtazapine**', 'Annual review + discussion about duration', 'Monitor weight'], ['**Lamotrigine** (mood stabilizer)', 'Annual review', '-'], ['**Levetiracetam** (epilepsy)', 'Annual review', '-'], ['**Atomoxetine** (ADHD, non-stimulant)', 'Annual review + BP monitoring', 'Monitor BP, cardiovascular effects'], ['**DPP-4 inhibitors** (vildagliptin, sitagliptin)', 'Annual review', 'No hypo risk as monotherapy'], ['**Montelukast**', 'Annual review', '-'], ['**Dementia medications** (donepezil, rivastigmine, memantine)', 'Annual review', 'Usually specialist-initiated'], ['**Levodopa preparations** (co-careldopa, co-beneldopa)', 'Annual review', 'Usually specialist-managed'], ['**Calcium + Vitamin D**', 'Annual review', '-']] },
    { type: 'subsection', id: 'required-action-all-green-zone', title: 'Required action for all GREEN zone medications', blocks: [
      { type: 'paragraph', content: '**Standard checks before 12-month prescription:**' },
      { type: 'list', content: '- ‚úì Patient stable on current dose 6+ months\n- ‚úì Annual review appointment booked\n- ‚úì Patient understands to contact if symptoms change' },
    ] },
  ] },
  { id: 'amber-zone', zone: 'amber', title: 'üü° AMBER ZONE: Quick Screening Table', blocks: [
    { type: 'paragraph', content: '**Use this table for FAST screening - detailed guidance follows below**' },
    { type: 'table', headers: ['Medication Class', 'Key Parameter', '12mo OK if:', 'MAX if:', 'Monitoring'], rows: [['[**ACEi/ARBs**](#ace-inhibitors-arbs)', '**eGFR**', '‚â•60', '<45 = 6mo max', '6-12 monthly renal + K+'], ['[**Metformin**](#metformin)', '**eGFR**', '>45', '<30 = STOP', '6-12 monthly renal'], ['[**DOACs**](#doacs-dabigatran-rivaroxaban)', '**CrCl (Cockcroft-Gault)**', 'Varies by drug', 'See table below', '6-12 monthly CrCl'], ['[**Spironolactone**](#spironolactone)', '**K+, eGFR**', 'NEVER 12mo', '6mo max always', '1wk, 1mo, then 6-monthly'], ['[**TCAs**](#tricyclic-antidepressants-tcas)', '**Age, cardiac risk**', 'Use judgment', '6mo safer', 'Annual + ECG if indicated'], ['[**Diuretics (loop)**](#diuretics-thiazides-and-loop)', '**Electrolytes**', 'Rarely', '6mo max', '3-6 monthly electrolytes'], ['[**Diuretics (thiazide)**](#diuretics-thiazides-and-loop)', '**Electrolytes**', '6-12mo', '-', '6-monthly electrolytes'], ['[**NSAIDs (Rx)**](#nsaids-prescription-strength)', '**Renal, triple whammy**', '6-12mo if alone', '3mo if triple whammy', '3-6 monthly if chronic'], ['[**Allopurinol**](#allopurinol)', '**eGFR**', '>60', '<30 = 6mo, dose reduce', '6-12 monthly renal'], ['[**Colchicine**](#colchicine)', '**eGFR**', '>60', '<30 = 3mo, dose reduce', '6-12 monthly renal'], ['[**SGLT-2i (empagliflozin)**](#sglt-2-inhibitors-empagliflozin)', '**eGFR**', '>30', '<20 = STOP', 'Annually (+ sick day rules)'], ['[**Sulfonylureas**](#sulfonylureas-gliclazide-glipizide)', '**Age, renal**', 'If <70 & eGFR >60', 'Age>70 or eGFR<60 = 6mo', 'Monitor for hypos'], ['[**GLP-1 agonists**](#glp-1-receptor-agonists-dulaglutide-liraglutide)', '**Injectable**', 'Yes (weekly injection)', '-', 'Annual review'], ['[**Gabapentin/Pregabalin**](#gabapentin-pregabalin)', '**eGFR, addiction risk**', 'eGFR >60', '<30 = 6mo, dose reduce', '6-12 monthly renal'], ['[**Oral steroids (chronic)**](#oral-corticosteroids-chronic-use)', '**Multiple**', 'NEVER 12mo', '3-6mo max', 'Multiple - see detail'], ['[**Bisphosphonates**](#bisphosphonates-alendronate-risedronate)', '**eGFR, dental**', 'eGFR >35', '<35 = specialist', 'Annual renal + dental check'], ['[**Levothyroxine**](#levothyroxine)', '**TSH**', 'Dose stable 6+ months', '12mo OK', 'Annual TSH once stable']] },
  ] },
  { id: 'amber-zone-detail', zone: 'amber', title: 'üü° AMBER ZONE: Individual Assessment Required - DETAILED GUIDANCE', blocks: [
    { type: 'paragraph', content: '**These medications CAN be prescribed for 12 months in SELECTED patients - check criteria first**' },
    { type: 'subsection', id: 'ace-inhibitors-arbs', title: 'ACE Inhibitors / ARBs', subtitle: 'enalapril, lisinopril, quinapril, irbesartan, losartan', blocks: [{ type: 'table', headers: ['eGFR', 'Prescription Duration', 'Monitoring Frequency', 'Action Required'], rows: [['**‚â•60**', '**12 months OK**', 'Annually', 'Renal function + K+ annually'], ['**45-59**', '**6-12 months** (GP discretion)', '6-monthly', 'Renal function + K+ 6-monthly'], ['**30-44**', '**MAX 6 months**', '4-6 monthly', 'Renal function + K+ 4-6 monthly'], ['**<30**', '**MAX 3-6 months**', '3-4 monthly', 'Specialist input may be needed']] }] },
    { type: 'subsection', id: 'metformin', title: 'Metformin', blocks: [{ type: 'table', headers: ['eGFR', 'Prescription Duration', 'Monitoring Frequency', 'Dose Limit'], rows: [['**>60**', '**12 months OK**', 'Annually', '3g/day max'], ['**45-60**', '**12 months OK**', 'Annually', '2g/day max'], ['**30-44**', '**MAX 6 months**', '6-monthly', '1g/day max (off-label, KDIGO supports 2g if >45)'], ['**15-29**', '**MAX 3 months**', '3-monthly', 'Specialist advice'], ['**<15**', '**CONTRAINDICATED**', '-', 'STOP metformin']] }] },
    { type: 'subsection', id: 'doacs-dabigatran-rivaroxaban', title: 'DOACs (Dabigatran, Rivaroxaban)', blocks: [{ type: 'table', headers: ['DOAC', 'Renal Threshold', 'Prescription Duration', 'Monitoring Frequency'], rows: [['**Dabigatran**', 'CrCl ‚â•50', '**12 months OK**', '6-12 monthly CrCl'], ['', 'CrCl 30-50', '**MAX 6 months** (dose reduce)', '6-monthly CrCl'], ['', 'CrCl <30', '**CONTRAINDICATED**', '-'], ['**Rivaroxaban**', 'CrCl ‚â•50', '**12 months OK**', '6-12 monthly CrCl'], ['', 'CrCl 30-49', '**MAX 6 months** (dose reduce)', '6-monthly CrCl'], ['', 'CrCl 15-29', '**MAX 3 months** (dose reduce)', '3-monthly CrCl'], ['', 'CrCl <15', '**AVOID**', '-']] }] },
    { type: 'subsection', id: 'spironolactone', title: 'Spironolactone', blocks: [{ type: 'table', headers: ['eGFR', 'K+', 'Prescription Duration', 'Monitoring'], rows: [['**>30**', '**<5.0**', '**MAX 6 months**', 'Renal + K+ at 1 week, 1 month, then 6-monthly'], ['**<30**', '-', '**CONTRAINDICATED**', '-'], ['-', '**‚â•5.0**', '**CONTRAINDICATED**', '-']] }] },
    { type: 'subsection', id: 'tricyclic-antidepressants-tcas', title: 'Tricyclic Antidepressants (TCAs)', blocks: [{ type: 'table', headers: ['Medication', 'Suitable for 12mo?', 'Why AMBER not GREEN', 'Monitoring'], rows: [['**Amitriptyline, Nortriptyline, Doxepin, Clomipramine**', '**Use clinical judgment - usually 6 months safer**', 'Cardiac risk, overdose risk, anticholinergic effects', 'ECG if cardiac risk factors, annual review']] }] },
    { type: 'subsection', id: 'diuretics-thiazides-and-loop', title: 'Diuretics (Thiazides and Loop)', blocks: [{ type: 'table', headers: ['Type', 'Prescription Duration', 'Monitoring', 'Notes'], rows: [['**Thiazides** (bendroflumethiazide, indapamide)', '**6-12 months**', 'Electrolytes + renal function 6-monthly', 'Initially closer monitoring, then 6-12 monthly once stable'], ['**Loop diuretics** (furosemide, bumetanide)', '**MAX 6 months**', 'Electrolytes + renal function 3-6 monthly', 'Especially in heart failure, more frequent monitoring']] }] },
    { type: 'subsection', id: 'nsaids-prescription-strength', title: 'NSAIDs (Prescription Strength)', subtitle: 'Naproxen, diclofenac, celecoxib', blocks: [{ type: 'table', headers: ['Situation', 'Prescription Duration', 'Monitoring', 'Risk Level'], rows: [['**Alone, young, normal renal function**', '**6-12 months** (if chronic use unavoidable)', '6-monthly renal function + BP', 'Low risk'], ['**With ACEi/ARB ("double whammy")**', '**MAX 6 months**', '3-6 monthly renal function + K+', 'Moderate risk'], ['**With ACEi/ARB + diuretic ("triple whammy")**', '**MAX 3 months**', 'Monthly renal function initially, then 3-monthly', '**HIGH RISK**'], ['**eGFR <60**', '**MAX 3-6 months**', '3-monthly renal function', 'High risk'], ['**Age >65**', '**MAX 6 months**', '6-monthly monitoring', 'GI bleed risk']] }] },
    { type: 'subsection', id: 'allopurinol', title: 'Allopurinol', blocks: [{ type: 'table', headers: ['eGFR', 'Prescription Duration', 'Dose Adjustment', 'Monitoring'], rows: [['**>60**', '**12 months OK**', 'Up to 900mg/day', 'Renal function annually'], ['**30-60**', '**6-12 months**', 'Max 300-600mg/day', 'Renal function 6-monthly'], ['**<30**', '**MAX 6 months**', 'Max 200mg/day, titrate slowly', 'Renal function 3-6 monthly']] }] },
    { type: 'subsection', id: 'colchicine', title: 'Colchicine', blocks: [{ type: 'table', headers: ['eGFR', 'Prescription Duration', 'Dose Adjustment', 'Risk'], rows: [['**>60**', '**12 months OK**', 'Standard dosing (0.5mg BD)', 'Low risk'], ['**30-60**', '**MAX 6 months**', 'Reduce dose by 50% (0.5mg daily)', 'Increased toxicity'], ['**<30**', '**MAX 3 months**', 'Max 0.5mg daily or alternate days', 'High toxicity risk']] }] },
    { type: 'subsection', id: 'sglt-2-inhibitors-empagliflozin', title: 'SGLT-2 Inhibitors (Empagliflozin)', blocks: [{ type: 'table', headers: ['eGFR', 'Prescription Duration', 'Dose', 'Monitoring'], rows: [['**>30**', '**12 months OK**', '10-25mg daily', 'Annual renal function'], ['**20-30**', '**12 months OK**', '10mg daily max', 'Annual renal function'], ['**<20**', '**STOP**', '-', '-']] }] },
    { type: 'subsection', id: 'sulfonylureas-gliclazide-glipizide', title: 'Sulfonylureas (Gliclazide, Glipizide)', blocks: [{ type: 'table', headers: ['Situation', 'Prescription Duration', 'Monitoring', 'Risk'], rows: [['**Age <70, eGFR >60**', '**12 months OK**', 'Monitor for hypoglycaemia', 'Low risk'], ['**Age >70 OR eGFR 30-60**', '**MAX 6 months**', '6-monthly monitoring, hypo awareness', 'Higher hypo risk'], ['**eGFR <30**', '**Reduce dose, MAX 6 months**', '3-6 monthly monitoring', 'High hypo risk']] }] },
    { type: 'subsection', id: 'glp-1-receptor-agonists-dulaglutide-liraglutide', title: 'GLP-1 Receptor Agonists (Dulaglutide, Liraglutide)', blocks: [{ type: 'table', headers: ['Type', 'Prescription Duration', 'Administration', 'Monitoring'], rows: [['**Dulaglutide**', '**12 months OK**', 'Weekly subcutaneous injection', 'Annual review, no routine glucose monitoring needed'], ['**Liraglutide**', '**12 months OK**', 'Daily subcutaneous injection', 'Annual review']] }] },
    { type: 'subsection', id: 'gabapentin-pregabalin', title: 'Gabapentin / Pregabalin', blocks: [{ type: 'table', headers: ['eGFR', 'Prescription Duration', 'Dose Adjustment', 'Risk'], rows: [['**>60**', '**12 months OK**', 'Standard dosing', 'Low risk if appropriate indication'], ['**30-60**', '**6-12 months**', 'Dose reduction needed', 'Accumulation risk'], ['**<30**', '**MAX 6 months**', 'Significant dose reduction', 'High toxicity risk']] }] },
    { type: 'subsection', id: 'oral-corticosteroids-chronic-use', title: 'Oral Corticosteroids (Chronic Use)', blocks: [{ type: 'table', headers: ['Duration of Use', 'Prescription Duration', 'Monitoring Required'], rows: [['**Long-term (>3 months)**', '**MAX 3-6 months**', 'Multiple - see below']] }] },
    { type: 'subsection', id: 'bisphosphonates-alendronate-risedronate', title: 'Bisphosphonates (Alendronate, Risedronate)', blocks: [{ type: 'table', headers: ['eGFR', 'Prescription Duration', 'Monitoring', 'Notes'], rows: [['**>35**', '**12 months OK**', 'Annual renal function', 'Take on empty stomach, sit upright 30min'], ['**<35**', '**Specialist review**', '-', 'Contraindicated in severe renal impairment']] }] },
    { type: 'subsection', id: 'levothyroxine', title: 'Levothyroxine', blocks: [{ type: 'table', headers: ['Situation', 'Prescription Duration', 'Monitoring'], rows: [['**Dose stable 6+ months**', '**12 months OK**', 'TSH annually (once stable)']] }] },
    { type: 'subsection', id: 'levetiracetam-epilepsy', title: 'Levetiracetam (Epilepsy)', blocks: [{ type: 'table', headers: ['eGFR', 'Prescription Duration', 'Dose Adjustment', 'Monitoring'], rows: [['**>80**', '**12 months OK**', 'Standard', 'Annual review'], ['**50-79**', '**12 months OK**', 'Reduce dose', '6-12 monthly renal function'], ['**30-49**', '**6-12 months**', 'Reduce dose significantly', '6-monthly renal function'], ['**<30**', '**MAX 6 months**', 'Reduce dose significantly', '3-6 monthly renal function']] }] },
    { type: 'subsection', id: 'nitrofurantoin-trimethoprim-chronic-uti-prophylaxis', title: 'Nitrofurantoin / Trimethoprim (Chronic UTI Prophylaxis)', blocks: [{ type: 'table', headers: ['Drug', 'eGFR', 'Prescription Duration', 'Monitoring'], rows: [['**Nitrofurantoin**', '>45', '**MAX 6 months**', '6-monthly LFTs, annual renal'], ['', '<45', '**CONTRAINDICATED**', '-'], ['**Trimethoprim**', '>15', '**6-12 months**', '6-monthly renal function']] }] },
  ] },
  { id: 'red-zone', zone: 'red', title: 'üî¥ RED ZONE: NOT Suitable for 12 Months', blocks: [
    { type: 'paragraph', content: '**These medications CANNOT be prescribed for 12 months - use 3 months or less**' },
    { type: 'subsection', id: 'controlled-drugs-legal-exclusion', title: 'Controlled Drugs (üî¥ LEGAL EXCLUSION)', blocks: [{ type: 'table', headers: ['Max supply', 'Examples'], rows: [['**Max 1 month**', 'All opioids: morphine, oxycodone, fentanyl, codeine, tramadol'], ['**Max 3 months**', 'ADHD stimulants (methylphenidate, dexamfetamine), benzodiazepines, zopiclone, cannabis preparations']] }] },
    { type: 'subsection', id: 'high-risk-medications-requiring-monitoring', title: 'High-Risk Medications Requiring Monitoring', blocks: [{ type: 'table', headers: ['Medication', 'Why Unsuitable', 'Max Duration', 'Monitoring Required'], rows: [['**Warfarin**', 'INR monitoring', '1-3 months', 'INR varies (weekly to monthly depending on stability)'], ['**Lithium**', 'Levels, renal, thyroid', '3 months', 'Levels 3-monthly (stable), renal + TFTs 3-6 monthly'], ['**Digoxin**', 'Levels, renal, ECG', '3 months', 'Levels + renal 3-6 monthly, ECG annually'], ['**Methotrexate**', 'FBC, LFTs', '3 months', 'FBC + LFTs monthly initially, then 2-3 monthly'], ['**Azathioprine**', 'FBC, LFTs', '3 months', 'FBC + LFTs monthly initially, then 3-monthly'], ['**Hydroxychloroquine**', 'Eye screening', '3-6 months', 'Annual eye exam after 5 years, FBC baseline'], ['**Mycophenolate**', 'FBC, LFTs', '3 months', 'FBC weekly initially, then monthly'], ['**Tacrolimus, Ciclosporin**', 'Levels, renal', '1-3 months', 'Levels frequently, renal monthly'], ['**Amiodarone**', 'Multiple monitoring', '3 months', 'TFTs, LFTs 6-monthly, CXR + ECG annually'], ['**Sodium valproate**', 'LFTs, FBC', '3 months', 'LFTs + FBC 6-monthly'], ['**Carbamazepine**', 'FBC, LFTs, Na+', '3 months', 'FBC + LFTs + Na+ 6-monthly'], ['**Phenytoin**', 'Levels, FBC', '3 months', 'Levels as needed, FBC 6-monthly'], ['**Insulin**', 'Regular adjustments', '3 months', 'Frequent glucose monitoring, dose adjustments']] }] },
    { type: 'subsection', id: 'antipsychotics-metabolic-monitoring-required', title: 'Antipsychotics (Metabolic Monitoring Required)', blocks: [{ type: 'table', headers: ['Medication', 'Monitoring Required', 'Max Duration', 'Risk Level'], rows: [['**Olanzapine, Clozapine**', 'Weight, glucose, lipids', '**3 months**', 'Highest metabolic risk'], ['**Quetiapine, Risperidone**', 'Weight, glucose, lipids', '**3 months**', 'Medium metabolic risk'], ['**Haloperidol, Chlorpromazine**', 'Weight, glucose', '**3-6 months**', 'Lower metabolic risk']] }] },
    { type: 'subsection', id: 'nsaids-chronic-use', title: 'NSAIDs (Chronic Use)', blocks: [{ type: 'paragraph', content: '**NOTE:** NSAIDs are in AMBER zone with restrictions - see AMBER section for details\n- If chronic use needed: MAX 6-12 months depending on situation\n- If "triple whammy": MAX 3 months (RED zone)' }] },
  ] },
  { title: 'Special Situations & Clinical Pearls', blocks: [
    { type: 'subsection', id: 'triple-whammy-warning-acei-arb-diuretic-nsaid', title: '"Triple Whammy" Warning (ACEi/ARB + Diuretic + NSAID)', blocks: [{ type: 'list', content: '- ‚ö†Ô∏è If patient on ACEi/ARB + diuretic:\n  - **Warn about over-the-counter NSAIDs**\n  - More frequent renal monitoring needed if NSAID required\n  - Consider 6 months instead of 12 months' }] },
    { type: 'subsection', id: 'polypharmacy-5-medications', title: 'Polypharmacy (‚â•5 medications)', blocks: [{ type: 'list', content: '- ‚ö†Ô∏è Consider **6 months** instead of 12 months for:\n  - Better medication reconciliation\n  - Earlier detection of adverse effects\n  - More frequent clinical review' }] },
    { type: 'subsection', id: 'age-75-years', title: 'Age >75 Years', blocks: [{ type: 'list', content: '- ‚ö†Ô∏è Physiological decline in renal function even if eGFR normal\n- ‚ö†Ô∏è For renally excreted drugs (DOACs, metformin, ACEi/ARBs):\n  - Consider 6-monthly reviews\n  - More frequent renal function monitoring' }] },
    { type: 'subsection', id: 'unstable-housing-transport-barriers', title: 'Unstable Housing / Transport Barriers', blocks: [{ type: 'list', content: '- ‚úì 12-month prescriptions may IMPROVE access for these patients\n- ‚úì Reduces cost and transport burden\n- ‚úì BUT ensure they can attend annual review (offer home visits if needed)' }] },
    { type: 'subsection', id: 'mori-patients', title: 'MƒÅori Patients', blocks: [{ type: 'list', content: '- ‚úì Consider barriers to access: will 12 months help or hinder?\n- ‚úì Proactive outreach for annual review\n- ‚úì Discuss what works best for patient and whƒÅnau\n\n---' }] },
  ] },
  ],
};
